1. Hormone Receptor-Positive Advanced Breast Cancer:

3. HR+ Advanced Breast Cancer: Introduction

4. Case Study Discussion

5. Case Study Discussion (cont)

6. ASCO Key Guideline Recommendations for HR+ MBC

7. ASCO Key Guideline Recommendations for HR+ MBC (cont)

8. SWOG 0226 Study: Anastrozole Alone vs Anastrozole + Fulvestrant in HR+ Breast Cancer

9. SWOG 0226: Results

10. FACT: Anastrozole Alone vs Anastrozole + Fulvestrant

11. FACT: Results

12. Emerging Therapies for HR+ Breast Cancer

13. BOLERO-2: Everolimus + Exemestane vs Placebo + Exemestane

14. BOLERO-2: Results

15. BOLERO-2: Most Common Grade 3/4 Adverse Events

16. Everolimus-Associated Stomatitis: Miracle Mouthwash vs Prednisolone Mouth Rinse

17. Miracle Mouthwash vs Prednisolone Mouth Rinse: Preliminary Results

18. CDKs and Their Cyclin Regulatory Subunits

19. PALOMA-1: Palbociclib + Letrozole vs Letrozole Alone

20. PALOMA-1: Results

21. PALOMA-2: Palbociclib + Letrozole vs Letrozole Alone

22. PALOMA-2: AE Summary

23. PALOMA-2: Results

24. MONALEESA-2: Ribociclib + Letrozole vs Letrozole in HR+ Advanced Breast Cancer

25. FALCON: Anastrozole vs Fulvestrant in HR+ Advanced or Metastatic Breast Cancer

26. FALCON: Results

28. MONALEESA-2 Ribociclib + Letrozole vs Letrozole in HR+ Advanced Breast Cancer

29. MONALEESA-2: Safety Profile

30. MONALEESA-2: Results

31. Treatment Recommendations for HR+ MBC

32. Conclusions

33. Abbreviations

34. Abbreviations